TY - JOUR
T1 - The evolution of cellular deficiency in GATA2 mutation
AU - Dickinson, Rachel E.
AU - Milne, Paul
AU - Jardine, Laura
AU - Zandi, Sasan
AU - Swierczek, Sabina I.
AU - McGovern, Naomi
AU - Cookson, Sharon
AU - Ferozepurwalla, Zaveyna
AU - Langridge, Alexander
AU - Pagan, Sarah
AU - Gennery, Andrew
AU - Heiskanen-Kosma, Tarja
AU - Ḧam̈al̈ainen, Sari
AU - Sepp̈anen, Mikko
AU - Helbert, Matthew
AU - Tholouli, Eleni
AU - Gambineri, Eleonora
AU - Reykdal, Sigrún
AU - Gottfreðsson, Magnús
AU - Thaventhiran, James E.
AU - Morris, Emma
AU - Hirschfield, Gideon
AU - Richter, Alex G.
AU - Jolles, Stephen
AU - Bacon, Chris M.
AU - Hambleton, Sophie
AU - Haniffa, Muzlifah
AU - Bryceson, Yenan
AU - Allen, Carl
AU - Prchal, Josef T.
AU - Dick, John E.
AU - Bigley, Venetia
AU - Collin, Matthew
PY - 2014/2/6
Y1 - 2014/2/6
N2 - Constitutive heterozygous GATA2 mutation is associated with deafness, lymphedema, mononuclear cytopenias, infection, myelodysplasia (MDS), and acute myeloid leukemia. In this study, we describe a cross-sectional analysis of 24 patients and 6 relatives with 14 different frameshift or substitution mutations of GATA2. A pattern of dendritic cell, monocyte, B, and natural killer (NK) lymphoid deficiency (DCML deficiency) with elevated Fms-like tyrosine kinase 3 ligand (Flt3L) was observed in all 20 patients phenotyped, including patients with Emberger syndrome, monocytopenia with Mycobacterium avium complex (MonoMAC), and MDS. Four unaffected relatives had a normal phenotype indicating that cellular deficiency may evolve over time or is incompletely penetrant, while 2 developed subclinical cytopenias or elevated Flt3L. Patients with GATA2 mutation maintained higher hemoglobin, neutrophils, and platelets and were younger than controls with acquired MDS and wild-type GATA2. Frameshift mutations were associated with earlier age of clinical presentation than substitution mutations. Elevated Flt3L, loss of bone marrow progenitors, and clonal myelopoiesis were early signs of disease evolution. Clinical progression was associated with increasingly elevated Flt3L, depletion of transitional B cells, CD56bright NK cells, näive T cells, and accumulation of terminally differentiated NK and CD81 memory T cells. These studies provide a framework for clinical and laboratory monitoring of patients with GATA2 mutation and may inform therapeutic decision-making.
AB - Constitutive heterozygous GATA2 mutation is associated with deafness, lymphedema, mononuclear cytopenias, infection, myelodysplasia (MDS), and acute myeloid leukemia. In this study, we describe a cross-sectional analysis of 24 patients and 6 relatives with 14 different frameshift or substitution mutations of GATA2. A pattern of dendritic cell, monocyte, B, and natural killer (NK) lymphoid deficiency (DCML deficiency) with elevated Fms-like tyrosine kinase 3 ligand (Flt3L) was observed in all 20 patients phenotyped, including patients with Emberger syndrome, monocytopenia with Mycobacterium avium complex (MonoMAC), and MDS. Four unaffected relatives had a normal phenotype indicating that cellular deficiency may evolve over time or is incompletely penetrant, while 2 developed subclinical cytopenias or elevated Flt3L. Patients with GATA2 mutation maintained higher hemoglobin, neutrophils, and platelets and were younger than controls with acquired MDS and wild-type GATA2. Frameshift mutations were associated with earlier age of clinical presentation than substitution mutations. Elevated Flt3L, loss of bone marrow progenitors, and clonal myelopoiesis were early signs of disease evolution. Clinical progression was associated with increasingly elevated Flt3L, depletion of transitional B cells, CD56bright NK cells, näive T cells, and accumulation of terminally differentiated NK and CD81 memory T cells. These studies provide a framework for clinical and laboratory monitoring of patients with GATA2 mutation and may inform therapeutic decision-making.
UR - http://www.scopus.com/inward/record.url?scp=84894078016&partnerID=8YFLogxK
U2 - 10.1182/blood-2013-07-517151
DO - 10.1182/blood-2013-07-517151
M3 - Article
C2 - 24345756
AN - SCOPUS:84894078016
SN - 0006-4971
VL - 123
SP - 863
EP - 874
JO - Blood
JF - Blood
IS - 6
ER -